Several classes of drugs, including DNMT inhibitors (e.g., azacytidine), HDAC inhibitors, and EZH2 inhibitors, are under investigation in preclinical models and clinical trials for hepatoblastoma [3,25,26,27,28,48,58]. Here, HDAC9 is linked to hepatoblastoma.